Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)
ConditionOvarian Cancer
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorNational Cancer Center, Korea
About this trial
Primary stage III-IV epithelial ovarian cancer randomizing between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC)
Eligibility criteria
Qualifiers
Signed and written informed consent,
Patients ≥18, <80 years old,
Diagnosed with histologically confirmed FIGO stage III-IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer treated with three cycles of neoadjuvant chemotherapy,
Treated with interval complete cytoreduction, or cytoreduction with no more than 2.5 mm depth of residual disease,
Disqualifiers
Diagnosed with non-epithelial ovarian carcinoma or borderline ovarian tumor
Patients who have not undergone neoadjuvant chemotherapy,
Interval cytoreduction with more than 2.5 mm depth of residual disease,
A life expectancy ≤3 months as clinically judged,
Trial design
Treatments tested in this trial
- Cisplatin
Treatment groups
520 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov